BioCryst Pharmaceuticals
BCRX
118 hedge funds and large institutions have $650M invested in BioCryst Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 24 closing their positions.
0% more call options, than puts
Call options by funds: $5.65M | Put options by funds: $5.65M
5% less funds holding
Funds holding: 124 → 118 (-6)
12% less capital invested
Capital invested by funds: $740M → $650M (-$89.8M)
14% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 37
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.63M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$2.44M |
| 4 |
Renaissance Technologies
New York
|
+$1.42M |
| 5 |
GC
Globeflex Capital
San Diego,
California
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 2 |
Millennium Management
New York
|
-$7.77M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$5.59M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.55M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.09M |
BCRX Hedge Fund Activity: Q4 2015 in Review
118 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2015, worth a combined $650M — down 12% from $740M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BCRX and 19 opened new positions — a net loss of 5 holders — while 37 trimmed existing stakes and 32 added.
The largest buyer was RA Capital Management, adding an estimated $18.9M. The largest seller was State Street, cutting an estimated $10.3M.
- 118 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2015, down from 124 in Q3 2015.
- Funds reported $650M of BioCryst Pharmaceuticals stock for Q4 2015, down 12% quarter-over-quarter.
- 19 funds opened new BioCryst Pharmaceuticals positions in Q4 2015 and 24 closed out, a net change of -5 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2015 was RA Capital Management, an estimated $18.9M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2015 was State Street, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2015.